GBM are now classified into three subtypes based on the presence and absence of IDH mutations: GBM IDH-wild type (90% of tumors), IDH-mutant (10%), and GBM IDH-NOS in which a full IDH evaluation cannot be performed. This evidence concerns the gene IDH1 and glioblastoma.